Reference
Huang P, et al. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. Journal of Gastrointestinal Cancer 53: 817-824, No. 3, Sep 2022. Available from: URL: http://www.springer.com/humana+press/gastroenterology/journal/12029
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1928, 50 (2022). https://doi.org/10.1007/s40278-022-25315-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-25315-0